Test vaccine added to hepatitis B treatment
Part of Digestive system, Infections clinical trials.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years
- You have chronic hepatitis B (not just past infection), and do not also have HIV, hepatitis C, or hepatitis D
- You have been on hepatitis B antiviral medicine for at least 12 months, and your HBV viral load is under 100 IU/ml
- You are not pregnant and not breastfeeding
- You have no allergy to hepatitis B or yeast-based vaccines
- You have recent blood tests showing liver values are not too high, and you do not have a fever or serious unstable illness right before shots
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental vaccine to help your immune system fight chronic hepatitis B, with the goal of controlling or possibly curing the infection. It's a early-stage study, so the main goals are safety and finding the right dose.
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study tests a two-step approach for chronic hepatitis B: first a shot called AHB-137, followed by another shot called TVAX-008. The goal is to see if this combination can help control the virus better.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.